VEGFA and age-related macular degeneration: This evidence suggests that pan-VEGF agents, although rapidly and effectively inhibiting neovascularization, vascular leakage, and other pathological changes in AMD or DR patients, exert detrimental effects in the long-term due to a loss of VEGF physiology at the ocular level (Amadio et al., 2016a; Gemenetzi et al., 2017; Fogli et al., 2018).